Clinical Trial

Trial Protocol ID USOR 23236_221530

Trial Description

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Patients with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Najeff Waseem, MD

Disease Types

Sponsor

  • GSK, LLC

ClinicalTrials.gov NCT ID

  • NCT06256588